Search

Brotizolam

Brotizolam has similar effects to short-acting benzodiazepines such as triazolam. Brotizolam is indicated for 2-4 weeks of treatment for severe or debilitating insomnia.

Zidovudine

A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. … The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription.

Rimiducid

It was designed to overcome limitations of current cellular immunotherapies used for cancer and other blood disorders by enhancing the control of the immune cell activity and function.

Lubazodone

Lubazodone (YM-992, YM-35,995) is an arylpiperazine antidepressant which was being developed as a treatment for depression and obsessive compulsive disorder, and reached phase II clinical trials, but was … It acts as a serotonin reuptake inhibitor and 5-HT2A receptor antagonist.

Chromic citrate

Abametapir

[A216178] Abametapir was first approved for use in the United States under the brand name Xeglyze on July 27, 2020.[L15163] … [L15153] The life cycle of head lice (_Pediculus capitis_) is approximately 30 days, seven to twelve of which are spent as eggs laid on hair shafts near the scalp.

CMLVAX100

It is developed by Breakthrough Therapeutics and has completed phase I of its clinical trial.

Iron isomaltoside 1000

Iron isomaltoside 1000 has been investigated for the treatment and basic science of Anemia, Gastric Cancer, Esophageal Cancer, Chronic Kidney Disease, and Anemia, Iron-Deficiency, among others.

Panitumumab

Panitumumab was granted FDA approval on 27 September 2006.[L17663]

Inclacumab

Inclacumab has been used in trials studying the treatment and prevention of Myocardial Infarction, Peripheral Arterial Disease (PAD), and Coronary Heart Disease, Graft Occlusion, Vascular.